Healthcare Industry News: cervical cancer
News Release - October 4, 2007
Cytyc Ships Cellient(TM) Automated Cell Block SystemsMARLBOROUGH, Mass.--(HSMN NewsFeed)--Cytyc Corporation (Nasdaq: CYTC ), a leading provider of surgical and diagnostic products targeting women's health and cancer diagnostics, announced that the first four Cellient(TM) Automated Cell Block Systems were shipped this week. The Cellient units were sent to Veteran's Administration Medical Centers in West Roxbury, MA and Charleston, SC, to New England Pathology Associates at Mercy Medical Center in Springfield, MA, and to Susquehanna Health Williamsport Hospital in Williamsport, Pennsylvania. The Cellient instrument is a fully automated system that allows individual cells or small tissue samples to be processed for histological examination.
"We are excited about the new Cellient System, as the cell block is an important adjunct in the diagnosis of cytologic specimens," said Bruce Dzuira, M.D., Chief of Cytopathology for New England Pathology Associates. "Cellient will allow us to view both cell morphology from cellular preparations and tissue architecture from the cell block on the same day, which will allow us to better serve our clinicians and patients."
Traditional methods for cell block preparation are labor intensive, sometimes taking as long as a day, and are extremely operator dependent, resulting in highly variable quality. The Cellient System is a fully-automated system that virtually eliminates operator dependence and provides standardized, consistent preparations in less than an hour.
"This is a significant milestone for the company and the result of a tremendous team effort," said Tony Kingsley, president of Cytyc's diagnostic products division. "The Cellient Automated Cell Block System extends our well-established cytopathology product line that includes the ThinPrep Imaging System and ThinPrep Pap Test, the standard of care for cervical screening, as well as the ThinPrep process for non-gynecologic applications. We are confident that Cellient will provide our customers the unparalleled performance and superior service associated with Cytyc and the ThinPrep brand."
Cytyc Corporation is a diversified diagnostic and medical device company that designs, develops, manufactures, and markets innovative and clinically effective diagnostic and surgical products. Cytyc's products cover a range of cancer and women's health applications, including cervical cancer screening, preterm birth screening, treatment of excessive menstrual bleeding, radiation treatment of early-stage breast cancer, and radiation treatment of patients with malignant brain tumors.
Cytyc is traded on The NASDAQ Global Select Market under the symbol CYTC. Cytyc and ThinPrep are registered trademarks of Cytyc Corporation. Cellient is a trademark of Cytyc Corporation.
Information set forth in this communication contains forward-looking statements, which involve a number of risks and uncertainties. Cytyc cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Without limiting the foregoing, Cytyc cannot guarantee that the merger with Hologic will be completed on a timely basis, if at all. Among other things, the transaction is subject to approval of both companies' stockholders as well as other customary closing conditions. In addition, each party has termination rights in certain limited circumstances. The risks and uncertainties included above are not exhaustive. The Joint Proxy Statement/Prospectus (File No. 333-144238), filed with the SEC by Hologic pursuant to Rule 424(b)(3) under the Securities Act of 1933, and the annual reports on Form 10-K, the quarterly reports on Form 10-Q, current reports on Form 8-K and other documents Cytyc has filed with the SEC contain additional factors that could impact the timing or completion of the transaction. Cytyc expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the parties' expectations or any change in events, conditions or circumstances on which any such statement is based.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.